Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Decrease in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a large drop in short interest in December. As of December 31st, there was short interest totaling 97,715 shares, a drop of 32.3% from the December 15th total of 144,277 shares. Based on an average trading volume of 50,816 shares, the days-to-cover ratio is presently 1.9 days. Based on an average trading volume of 50,816 shares, the days-to-cover ratio is presently 1.9 days.

Innovent Biologics Stock Down 2.7%

Shares of Innovent Biologics stock opened at $11.17 on Friday. Innovent Biologics has a 12-month low of $3.91 and a 12-month high of $15.12. The stock’s fifty day moving average is $11.15 and its 200-day moving average is $11.63.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).